DIMA describes itself as designing and manufacturing medical implants for pelvic floor pathologies since 1994, combining technical development with clinical experience and controlled production. Its own product pages organize offerings around female urinary incontinence, pelvic organ prolapse, male urinary incontinence, surgical meshes, agenesis and surgical instruments. The company also lists veterinary products and other services. On the regulatory side, the linked FDA record shows one submission: KIM BLUE, received 6 July 2026 and cleared 16 October 2026 as substantially equivalent under the traditional 510(k) pathway. [3][4][6][1]
The KIM BLUE clearance
KIM BLUE was filed under K number K262284 by Desarrollo e Investigación Médica Aragonesa S.L., with a Calatayud, Spain address on the filing. The device sits in product code OTN, regulation 878.3300, device class 2, with the openFDA device name describing a synthetic surgical mesh for urogynecologic stress urinary incontinence, retropubic or transobturator. The advisory committee is listed as General, Plastic Surgery, with a review advisory committee of Gastroenterology, Urology. The decision code SESE denotes substantially equivalent, and the submission carried a summary rather than a statement. [1][8]
The submission was a traditional 510(k) with no third-party review flag, received 6 July 2026 and decided 16 October 2026. The FDA database page for the same K number was last updated 26 October 2026. These dates describe one filing only; they say nothing about the company's wider pipeline or commercial status. [1][2]
Company identity and stated scope
DIMA's own site states that since 1994 it has designed and manufactured medical implants for treating pelvic floor pathologies, and it presents clinically driven design and specialized manufacturing as its operating principles. The medical products page lists female urinary incontinence, pelvic organ prolapse, male urinary incontinence, surgical meshes, agenesis and surgical instruments as categories. A separate veterinary products section and an other services section appear in the site navigation. [3][4][6]
The site names Neomedic as a distributor and states that DIMA is part of ARA Health. Those relationships are reported as the company presents them; the public documents do not document ownership terms, and no parent or brand should be treated as the FDA applicant. The FDA applicant of record for K262284 is Desarrollo e Investigación Médica Aragonesa S.L. itself. [4][3][1]
What the filing record does and does not show
The supplied portfolio snapshot, taken as of 20 November 2026, links one record to this company, a 510(k) with decision SESE. The record sample contains that same single entry, so the sample decision count and the collection decision count both equal one. This is a count of supplied filings at a point in time, not a measure of total portfolio, sales or safety performance. [1]
No premarket approval, de novo, recall or other pathway record for this company appears in the public information. The FDA openFDA disclaimer notes that its data should not be relied on for medical care decisions and should be assumed unvalidated. Nothing in the sources describes clinical outcomes, patient selection or instructions for use of KIM BLUE. [5][1]
Reading the record alongside the product pages
The company's product taxonomy and the single cleared device are consistent in subject matter: pelvic floor and urinary incontinence implants. The product pages do not map individual catalog items to K numbers, so which listed products correspond to KIM BLUE, and whether other listed products hold United States clearances, remains unknown from the public documents. [6][1]
For industry readers, the documented position is narrow and specific: a Zaragoza-province manufacturer with a long stated history in pelvic floor implants and one 2026 traditional 510(k) clearance for a urogynecologic mesh. Broader claims about the company's regulatory footprint would require records not present here. [3][1][4]

